Core Viewpoint - The investigation by Halper Sadeh LLC focuses on the fairness of the acquisition of Dynavax Technologies Corporation by Sanofi at a price of $15.50 per share in cash, raising concerns about potential violations of federal securities laws and fiduciary duties to shareholders [1][2]. Group 1: Investigation Details - The investigation examines whether Dynavax and its board failed to secure the best possible consideration for shareholders [2]. - It questions if Sanofi is underpaying for Dynavax and whether all material information necessary for shareholders to assess the merger was disclosed [2]. Group 2: Legal Actions and Representation - Halper Sadeh LLC may seek increased consideration for Dynavax shareholders, additional disclosures, or other forms of relief related to the proposed transaction [3]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [3]. Group 3: Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

德纳维制药(DVAX.US)盘前暴涨超37%，报15.3美元。消息面上，赛诺菲宣布，同意以每股15.5美元的 现金收购德纳维制药，旨在扩充其目前以流感疫苗业务为核心的疫苗产品线。该报价较达德纳维制药周 二的收盘价溢价39%，交易价值约22亿美元。此项收购有望于2026年第一季度完成。(格隆汇) ...

Core Viewpoint - Sanofi announced the acquisition of Dynavax Technologies Corporation for $2.2 billion, enhancing its influence in the adult immunization sector by combining Dynavax's vaccines with Sanofi's global scale and development capabilities [2][5]. Group 1: Acquisition Details - Sanofi will initiate a cash tender offer to acquire all outstanding shares of Dynavax at $15.50 per share, representing a premium of approximately 39% over Dynavax's closing price on December 23, 2025, and a 46% premium over the three-month volume-weighted average price [3][11]. - The transaction has received unanimous approval from Dynavax's board and is expected to close in the first quarter of 2026, subject to customary closing conditions [11]. Group 2: Product Portfolio and Market Opportunity - Dynavax's HEPLISAV-B, an adult hepatitis B vaccine, offers a two-dose regimen within one month, achieving high levels of seroprotection faster than traditional three-dose vaccines administered over six months [5]. - The acquisition includes Dynavax's shingles vaccine candidate (Z-1018), currently in Phase 1/2 clinical development, and other vaccine pipeline projects [5][8]. - There is a significant unmet public health need for hepatitis B and shingles vaccines, with nearly 100 million adults in the U.S. born before 1991 remaining unvaccinated, exposing them to infection risks [8]. Group 3: Financial Performance - Dynavax reported total revenues of $94.9 million in Q3 2025, an 18% increase from $80.6 million in Q3 2024, with HEPLISAV-B net product revenue rising by 13% [6]. - The company achieved a GAAP net income of $26.9 million in Q3 2025, reflecting a 53% increase compared to $17.6 million in Q3 2024 [6].

Group 1 - French drugmaker Sanofi has agreed to acquire U.S. vaccines company Dynavax Technologies Corporation for approximately $2.2 billion (1.87 billion euros) [1]

Group 1 - Sanofi has agreed to acquire Denali Therapeutics for approximately $2.2 billion to expand its vaccine product line focused on influenza vaccines [1] - The acquisition will be at a cash price of $15.50 per share, representing a 39% premium over Denali's closing price on Tuesday [1] - This acquisition will provide Sanofi with an already marketed hepatitis B vaccine and an experimental shingles vaccine currently in early human trials, enhancing its presence in the adult vaccination market [1] Group 2 - Sanofi emphasized that the acquisition is not expected to impact its financial guidance for 2025 and is anticipated to be completed in the first quarter of 2026 [1] - Shortly before announcing the acquisition, Sanofi disclosed that its investigational multiple sclerosis drug tolebrutinib faced a rejection from the FDA [2] - The R&D head of Sanofi expressed disappointment regarding the FDA's decision, noting a significant and substantive shift in direction compared to previous feedback from the agency [3]

Group 1 - The cash deal aims to enhance the French drugmaker's immunization portfolio following setbacks in clinical trials [1]

Core Viewpoint - Sanofi has announced an agreement to acquire Dynavax Technologies Corporation for $15.50 per share, representing a 39% premium over Dynavax's closing share price on December 23, 2025, enhancing Sanofi's adult immunization portfolio with Dynavax's vaccines [1][4]. Group 1: Acquisition Details - The acquisition includes Dynavax's marketed adult hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate Z-1018, which is in phase 1/2 clinical development [2]. - The total equity value of the acquisition is approximately $2.2 billion, with the offer price reflecting a 46% premium over the 3-month volume-weighted average price of Dynavax as of December 23, 2025 [4]. - The transaction has been unanimously approved by Dynavax's board of directors and is expected to close in the first quarter of 2026, subject to customary closing conditions [5][7]. Group 2: Product Information - HEPLISAV-B is a two-dose adult hepatitis B vaccine that provides high levels of seroprotection faster than traditional three-dose vaccines [2][8]. - The shingles vaccine candidate Z-1018 aims to address significant public health needs, as shingles affects one in three adults over their lifetime [3]. Group 3: Market Opportunity - There is a significant unmet health need for hepatitis B and shingles vaccination, particularly among nearly 100 million unvaccinated adults in the US born before 1991 [3]. - Chronic hepatitis B infection can lead to severe liver damage, while shingles can cause long-term nerve pain and other serious complications [3].

NEW YORK (AP) — Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day. The S&P 500 index rose 22.26 points, or 0.3%, to 6,932.05. The Dow Jones Industrial Average added 288.75, or 0.6%, to close at 48,731.16, and the Nasdaq composite added 51.46, or 0.2%, to 23,613.31 Trading was extremely light as markets closed early for Christmas Eve and will be closed for Christmas Thursday. Roughly 1.8 billion shares traded on the New York Stock Exchange on Wednesday, which ...

Core Viewpoint - Dynavax Technologies Corporation is actively participating in the 8th Annual Evercore Healthcare Conference, indicating its ongoing engagement with investors and the healthcare community [1]. Company Overview - Dynavax is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to combat infectious diseases [3]. - The company has two commercial products: HEPLISAV-B, a hepatitis B vaccine approved in the U.S., EU, and UK for adults aged 18 and older, and the CpG 1018 adjuvant, utilized in HEPLISAV-B and various adjuvanted COVID-19 vaccines [3]. Investor Engagement - The upcoming fireside chat at the Evercore Healthcare Conference is scheduled for December 2nd at 2:10 p.m. ET, which will be accessible via the company's website [1][2].

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]